Technical Analysis for AYTU - Aytu BioScience, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| See historical AYTU trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Resistance | Bearish | 0.83% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.83% | |
| MACD Bullish Signal Line Cross | Bullish | 0.83% | |
| Wide Bands | Range Expansion | 0.83% | |
| 20 DMA Resistance | Bearish | 0.83% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.83% | |
| Wide Bands | Range Expansion | 0.83% | |
| Up 3 Days in a Row | Strength | 0.83% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.
Healthcare Organ Systems Prostate Cancer Alcohols Hormones Ketones Company's Pipeline Urinary Tract Infections Androstanes Male Infertility Testosterone
Healthcare Organ Systems Prostate Cancer Alcohols Hormones Ketones Company's Pipeline Urinary Tract Infections Androstanes Male Infertility Testosterone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more AYTU news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 2.61 |
| 52 Week Low | 0.68 |
| Average Volume | 116,871 |
| 200-Day Moving Average | 1.526 |
| 50-Day Moving Average | 1.3112 |
| 20-Day Moving Average | 1.2151 |
| 10-Day Moving Average | 1.0971 |
| Average True Range | 0.1256 |
| ADX | 21.15 |
| +DI | 20.9179 |
| -DI | 19.6326 |
| Chandelier Exit (Long, 3 ATRs ) | 1.1632 |
| Chandelier Exit (Short, 3 ATRs ) | 1.2868 |
| Upper Bollinger Band | 1.5098 |
| Lower Bollinger Band | 0.9204 |
| Percent B (%b) | 0.51 |
| BandWidth | 48.506296 |
| MACD Line | -0.0656 |
| MACD Signal Line | -0.0775 |
| MACD Histogram | 0.0119 |
| Fundamentals | Value |
|---|---|
| Market Cap | 4.91 Million |
| Num Shares | 4.02 Million |
| EPS | -48.30 |
| Price-to-Earnings (P/E) Ratio | -0.03 |
| Price-to-Sales | 4.58 |
| Price-to-Book | 0.76 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.40 | ||||
| Resistance 3 (R3) | 1.40 | 1.33 | 1.37 | ||
| Resistance 2 (R2) | 1.33 | 1.29 | 1.34 | 1.36 | |
| Resistance 1 (R1) | 1.28 | 1.26 | 1.25 | 1.28 | 1.35 |
| Pivot Point | 1.21 | 1.21 | 1.20 | 1.22 | 1.21 |
| Support 1 (S1) | 1.16 | 1.17 | 1.13 | 1.16 | 1.09 |
| Support 2 (S2) | 1.09 | 1.14 | 1.10 | 1.08 | |
| Support 3 (S3) | 1.04 | 1.09 | 1.07 | ||
| Support 4 (S4) | 1.04 |
